Ryan Crisman
@crisman_ryan
Followers
23
Following
76
Media
6
Statuses
59
Biotech junkie (co-founder of Umoja Biopharma) and brewery owner (Long Table Brewhouse). Thoughts are my own.
Joined February 2021
We are excited to announce the opening of our new development and manufacturing facility, The CLIMB, in Louisville, CO. The facility will help accelerate the development of our therapeutic candidates. Read more in our press release: https://t.co/q6bn7UJi0F
0
1
2
As soon as the cells are taken out of the body it’s a negative equation.
Our CEO, @andyscharenberg, joined @Erin_Harris1 for the latest episode of the #CellAndGenePodcast. Listen to learn about our lentiviral vector manufacturing facility called The CLIMB and our approach to developing next generation #immunotherapies: https://t.co/KUpBYTnKIo
0
0
0
New data shows that in vivo CAR-T cell therapies have the potential to unlock a new class of therapeutics. Researchers hope this technique will reduce the cost and complexity of administering CAR-Ts and broaden their application. #celltherapy
https://t.co/o1lW0wZ2Fa
fiercebiotech.com
Umoja Biopharma’s VivoVec platform has generated in vivo chimeric antigen receptor T cells, or CAR-T cells, in nonhuman primates, according to new data presented by the company Sept. | The company's...
0
3
4
Umoja's: best-in-class in vivo CAR T therapy shows positive first signs
fiercebiotech.com
Umoja Biopharma’s VivoVec platform has generated in vivo chimeric antigen receptor T cells, or CAR-T cells, in nonhuman primates, according to new data presented by the company Sept. | The company's...
0
1
1
Today at the @CAR_TCell Summit, we presented data from our ongoing NHP study of our VivoVec™ platform, which includes the rapid, durable #CARTcell generation in vivo after a single infusion of #VivoVec particles. Learn more: https://t.co/9OAMRm6EgK
#CARTCR #immunotherapy
1
5
3
We are looking forward to presenting at the upcoming 8th @CAR_TCell Summit on September 1 in Boston. Our EVP, Byoung Ryu, PhD, will share data from our ongoing non-human primate study for the first time. Find details here: https://t.co/5QuHst75GL
#CARTCR #immunotherapy
0
2
3
At Umoja, we made the strategic decision to bring manufacturing in-house early on with The CLIMB, allowing us to gain control of our supply chain. Shorter lead times, enhanced R&D, & seamless scalability will be game changers for us. Read more here:
0
1
3
We are proud to share that our COO, David Fontana, PhD, will be presenting Umoja's mission, pipeline & technology at @IAmBiotech BIO International Convention on June 7 at 4:30 pm ET. Check out our press release for details: https://t.co/zRdy0wQW1l
#BIO2023 #StandUpForScience
0
1
4
We are presenting new preclinical data at @ASGCTherapy’s #ASGCT23 that demonstrates the potent in vivo #CART cell generation and durable anti-tumor activity of our #VivoVec, #RACR, and #TumorTag platforms. Check out our presentation highlights: https://t.co/5z3X5WQowV
0
2
11
We are excited to announce we will be presenting new in vivo #CART data at the 26th @ASGCTherapy Annual Meeting. Learn more about our oral and poster presentations here: https://t.co/yGBt6zyczZ
#ASGCT23
0
2
4
In this second @OutsourcedPharm article with @Louis_Garguilo our CEO @andyscharenberg and CTO @crisman_ryan discuss Umoja’s focus on bringing our therapeutics into clinical application and why we chose Colorado for the location of The CLIMB. Read here:
outsourcedpharma.com
If any of you have thoughts of building internal development and manufacturing facilities (to supplement or augment your outsourcing,) this is a discussion for you. It describes how on cell-therapy...
0
3
9
I’m pleased to have the opportunity to highlight Umoja’s in vivo CAR T cell technology at this year’s #IO360. Many patients don’t respond to current immunotherapies, and we believe our approach may help bring transformative treatments to patients.
0
1
8
0
0
1
In this @pharmasalmanac Q&A, our VP and Head of Immunology Ryan Larson, PhD, discusses how Umoja’s talented team and differentiated technology platforms aim to overcome major challenges in the current cell and #GeneTherapy space. Read more here:
0
1
3
We are excited to be presenting at @jpmorgan’s #JPM2023 next week! We are looking forward to sharing Umoja’s vision with our industry peers and the investment community. Read our full press release for more details: https://t.co/ms8hAWpbx3
0
1
2
We have entered a research agreement with IASO Biotherapeutics to bring together our iCIL platform with IASO’s chimeric antigen receptors to create next-generation cell therapies for #AML and other hematological malignancies. Read more: https://t.co/NuoiFVSN81
#OffTheShelf
0
1
5
We are excited to present three posters at @sitcancer from November 11-14. We will share updates on our complementary cell therapy platforms for in vivo CAR T cell therapies and #RACR-induced cytotoxic lymphocytes (#iCIL). Read our press release: https://t.co/sTfNbt4OZw
#SITC2022
0
1
6
1/ HOW OLD ARE YOU? There’s 1. Chronological age––when you were born 2. Biological age–– your different cells, organs + systems are different ages Lux has had long standing theses + interest in mechanics of intracellular, intercellular and emergent phenomena of CHRONOBIOLOGY
6
40
300
Got some summer riding at elevation this weekend. Loving #breckenridge #frisco #coloradotrail this time of year. Great #umojabiopharma swag for the ride
0
0
1